Erstad Derek J, Tager Andrew M, Hoshida Yujin, Fuchs Bryan C
Division of Surgical Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Center for Immunology and Inflammatory Diseases, Fibrosis Research Center, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Mol Cell Oncol. 2017 Mar 31;4(3):e1311827. doi: 10.1080/23723556.2017.1311827. eCollection 2017.
Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.
利用转录组荟萃分析，我们最近确定自分泌运动因子（ATX）-溶血磷脂酸（LPA）通路是人类肝硬化患者肝细胞癌（HCC）风险的一个调节因子。对该通路进行药物靶向治疗可减少动物体内的纤维化进展和HCC发展，这表明ATX-LPA信号传导是一种针对肝硬化和HCC的新型化学预防策略。
